2023
Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
Merkin R, Chiang V, Goldberg S. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances In Medical Oncology 2023, 15: 17588359231175438. PMID: 37275964, PMCID: PMC10233588, DOI: 10.1177/17588359231175438.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsBrain metastasesTargetable genetic alterationsLocal therapyLung cancerStereotactic radiosurgeryDeath 1 ligand 1 expressionManagement of BMSole metastatic siteStage IV diseaseWhole brain radiotherapyLigand 1 expressionPD-L1 expressionProspective clinical trialsTime of diagnosisManagement of patientsCell lung cancerCancer-related deathGenetic alterationsCentral nervous systemGenetic driver alterationsAnaplastic lymphoma kinaseEpidermal growth factor receptorGrowth factor receptorUpfront radiotherapy
2015
Evolution of multidisciplinary brain metastasis management: case study and literature review.
Colaco R, Martin P, Chiang V. Evolution of multidisciplinary brain metastasis management: case study and literature review. The Yale Journal Of Biology And Medicine 2015, 88: 157-65. PMID: 26029014, PMCID: PMC4445437.Peer-Reviewed Original ResearchConceptsBrain metastasesManagement of BMProgression-free survivalLocal tumor controlLong-term survivorsNeurocognitive side effectsBrain metastasis managementSymptom reliefTumor burdenTumor controlCancer patientsTreatment modalitiesMetastasis managementSide effectsRadiation modalitiesFunctional independenceContemporary managementPatientsLiterature reviewSurvivalModalitiesOverall qualityCoordinated approachManagementPrognosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply